RT Journal Article
T1 Consensus document on the progression and treatment response criteria in gastroenteropancreatic neuroendocrine tumors.
A1 Merino-Casabiel, X
A1 Aller, J
A1 Arbizu, J
A1 Garcia-Figueiras, R
A1 Gonzalez, C
A1 Grande, E
A1 Jimenez-Fonseca, P
A1 Sevilla, M I
A1 Capdevila, J
K1 Diagnostic imaging
K1 Molecular imaging
K1 Neuroendocrine tumors
K1 Nuclear medicine
K1 Radionuclide imaging
AB Gastroenteropancreatic neuroendocrine tumors are a heterogeneous group of low incidence neoplasms characterized by a low proliferative activity and slow growth. Their response to targeted therapies is heterogeneous and often does not lead to tumor shrinkage. Thus, evaluation of the therapeutic response should differ from other kind of tumors. To answer relevant questions about which techniques are best in the assessment of progression or treatment response a RAND/UCLA-based consensus process was implemented. Relevant clinical questions were listed followed by a systematic search of the literature. The expert panel answered all questions with recommendations, combining available evidence and expert opinion. Recommendations were validated through a questionnaire and a participatory meeting. Expert recommendations regarding imaging tools for tumor assessment and evaluation of progression were agreed upon. Available imaging techniques were reviewed and recommendations for best patient monitoring practice and the best way to evaluate treatment response were formulated.
PB Springer
YR 2018
FD 2018-05-15
LK http://hdl.handle.net/10668/12473
UL http://hdl.handle.net/10668/12473
LA en
NO Merino-Casabiel X, Aller J, Arbizu J, García-Figueiras R, González C, Grande E, et al. Consensus document on the progression and treatment response criteria in gastroenteropancreatic neuroendocrine tumors. Clin Transl Oncol. 2018 Dec;20(12):1522-1528
DS RISalud
RD Apr 5, 2025